RESUMO
Se presenta el caso de un paciente masculino de un año de edad, con antecedentes previos de asma bronquial. Refiere la mamá que hacía 11 días el paciente había sufrido una caída, en ese momento se encontraba ingiriendo maní, pasadas unas horas aparece tos seca, la madre consultó al policlínico de su área donde le pusieron tratamiento con prednisona oral por 3 días, con lo cual nota discreta mejoría, sin desaparecer del todo la tos. Al sexto día del evento comenzó a presentar fiebre de 38°C haciendo dos picos al día, los cuales cedían con la administración de Dipirona en tableta. Debido a que los síntomas persistían (tos y fiebre) la madre lleva nuevamente al niño al facultativo, donde le realizaron radiografía de tórax, observando una imagen atelectásica a nivel del pulmón derecho, por lo que deciden remitir al Hospital Juan Manuel Márquez(AU)
The case is presented of a male patient of one year of age, with antecedents of bronchial asthma. His mother referred that 11 days ago the patient had fallen, at the moment when he was consuming peanuts. Some hours later dry cough appears. The mother consulted the area polyclinic, where the patient was prescribed prednisone by oral way for three days, with which she notices some improvement, but cough did not disappear totally. Six days after the event, the patients presented a 100ºF fever with peaks daily, which drifted when dipyrone pills were administered. As long as the symptoms prevailed (cough and fever), the mother takes the child again to the doctors, where he is taken a thorax radiography, which shows an atelectasis image at the right lung level, a reason why he is decided to be referred to Juan Manuel Márquez Hospital(AU)
Assuntos
Humanos , Masculino , Lactente , Atelectasia Pulmonar/etiologia , Corpos EstranhosRESUMO
Respiratory papillomatosis is a life-spoiling disease due to its high recurrence rate. Interferon (IFN)alpha-2b treatment, adjuvant to surgery, was assessed for its contribution to disease control and patient quality of life improvement. One hundred and sixty-nine patients (85 children and 84 adults) were included after surgical removal of the lesions followed by intramuscular IFN alpha-2b (Heberon alfa R, Heber Biotec), starting with 10(5) IU/Kg weight in children or 6 x 10(6) IU in adults, three times per week. The dose was reduced monthly, if no relapses occurred, until a monthly maintenance with 5 x 10(4) IU/Kgof weight in children or 3 x 10(6) IU in adults up to two years. In case of relapse, it was surgically removed and the patient returned to the higher dose level. The relapse frequency decreased significantly in 77 percent (69/90) of the recurrent patients both in children (34/46, 74 per cent) and adults (35/44, 79 per cent). Among patients included after their first papilloma, 67 per cent (44/66) had complete (no relapses) or partial (only one relapse) responses (children: 15/33, 45 per cent; adults 29/33, 88 per cent). One hundred and eighteen patients (73 per cent) concluded the treatment without lesions (children: 58 per cent; adults 82 per cent), while the rest showed a significant reduction in the number and size of lesions. IFN was well tolerated. Sixty-two patients (38 per cent) did not have adverse events. The main adverse reactions were fever (59 per cent), chills (24 per cent), arthralgias and myalgias (14 per cent) and headache (10 per cent). One patient developed anti-IFN alpha neutralizing antibodies and became resistant to treatment with recombinant IFN alpha-2b; he responded to natural leucocyte IFN alpha. Treatment with IFN alpha-2b, as an adjuvant to surgery represents a favourable and safe therapeutic alternative for patients with recurrent respiratory papillomatosis.